NanoViricides Inc. (NNVC)

[loanranger]

"NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate NV-CoV-2 thereby resulting in the dual-acting drug candidate NV-CoV-2-R with the promise of a potential pan-coronavirus cure."
https://www.prnewswire.com/news-releases/significantly-improved-safety-profile-and-metabolism-of-remdesivir-observed-due-to-encapsulation-in-nanoviricides-drug-candidate-enabling-potential-highly-effective-pan-coronavirus-antiviral-drug-301382343.html

That was two months ago.

"In brief, our platform technology based NV-387-encapsulated-RDV (NV-CoV-2-R) drug has a dual effect on coronaviruses. First, NV-CoV-2 itself as an antiviral regimen. Secondly, RDV is protected from plasma-mediated degradation in transit, rendering altogether the safest and an efficient regimen against COVID-19."
https://www.biorxiv.org/content/10.1101/2021.11.24.469813v1.full (note...preprint, not peer reviewed)

That was dated 11/26. (see Note)


"Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo."
https://www.nejm.org/doi/full/10.1056/NEJMoa2116846

That was last week.



Note:
One of the authors of the Preprint is listed as Jayant Tatake, who is referenced in the latest NNVC 10-K:
" On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $150,000. In addition, the Company issued 1,340 shares of Series A preferred stock and 1,786 shares of common stock upon entering into the agreement, and will issue an additional 1,340 shares of Series A preferred stock and 1,786 shares of common stock on each anniversary date of the agreement. The shares of Series A preferred stock were issued in recognition of Dr. Tatake’s work towards the achievement of several patents by the Company."

Something changed at some point (when?) because the pre-print and JT's Linkedin listing describe him as "VP, R&D at AllExcel, Inc.,"
Ultimately, who pays him?

Al of the pre-print authors are employees of either Nanoviricides or Allexcel:

Author Information

Anil Diwan1, Ph.D., Ashok Chakraborty2*, Ph.D., Vijetha Chiniga2, MS, Vinod Arora2, Ph.D., Preetam Holkar2, MS., Yogesh Thakur2, MS., Jay Tatake2, Ph.D., Randall Barton1, Ph.D., Neelam Holkar2, MS. and Bethany Pond2, MS

1Nanoviricides, Inc., Shelton, CT, USA
2AllExcel, Inc., West Haven, CT, USA

So this is an interesting claim:

Conflict of Interests

Authors, Anil Diwan and Randall Barton are employed by the company Nanoviricides, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

CNBC published an interesting release some time ago:
"CNBC also asked NanoViricides to clarify the relationship between TheraCour, AllExcel and NanoViricides, and any cash payments to AllExcel, but NanoViricides did not respond."
"“The patents have been assigned to AllExcel, Inc., the Company at which the groundbreaking work was performed. AllExcel, Inc. has contractually transferred this intellectual property to TheraCour Pharma, Inc.,” the company said in the 10-Q."
Diwan was a no-show for an agreed-to CNBC interview.
“The answers to all of your other questions are already publicly available in our press releases, regulatory filings, and on our website,” the statement from Diwan said.
https://www.cnbc.com/2020/07/14/biopharma-nanoviricides-sees-stock-soar-on-coronavirus-claims.html